BioCryst Pharmaceuticals Q4 Earnings Call Highlights

Core Insights - BioCryst Pharmaceuticals received FDA approval for ORLADEYO oral pellets for children aged 2 to less than 12 in December 2025, addressing a significant unmet need in hereditary angioedema (HAE) treatment [1] - The company reported strong financial performance for 2025, with ORLADEYO revenue reaching $601.8 million, a 38% increase year-over-year, and expects continued growth in 2026 [3][4] - BioCryst is advancing its pipeline, including navenibart, which is in pivotal Phase 3 trials, and BCX17725 for Netherton syndrome, with promising early results [6][10] Financial Performance - ORLADEYO revenue for 2025 was $601.8 million, up 38% year-over-year, and 43% when excluding the European business sold in October [3][4] - Non-GAAP operating profit rose to $214 million, a 198% increase year-over-year, marking the highest in company history [13] - The company ended 2025 with $337.5 million in cash and investments and entered a $400 million financing facility with Blackstone Life Sciences [14] Product Development and Pipeline - Navenibart is currently enrolling in the Phase 3 Alpha Orbit trial, targeting approximately 145 patients by mid-2026, with a BLA submission expected after mid-2027 [4][6] - Phase 2 data for navenibart showed significant attack-rate reductions, with mean reductions of 90-92% [7] - The company is also advancing BCX17725 for Netherton syndrome, with completed Phase 1 trials showing safety and tolerability [10][11] Market Positioning and Strategy - BioCryst views the HAE market as "structurally segmented," emphasizing that treatment choices are driven by patient needs rather than a single efficacy leader [3] - The pediatric launch of ORLADEYO is included in 2026 guidance but is expected to be a small contributor in the near term [5] - The company implemented a 9% price increase for ORLADEYO in January, expecting to net about half of that increase [15]